ReviewJournal of geriatric cardiology : JGC2018
Treatment of coronary in-stent restenosis: a systematic review.
Review in Journal of geriatric cardiology : JGC, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Pooled it
- Drug-coated balloons versus drug-eluting stents in patients with in-stent restenosis: An updated meta-analysis with trial sequential analysis.Journal of cardiothoracic surgery · 2024Pooled it
- Influences of Stent Design on In-Stent Restenosis and Major Cardiac Outcomes: A Scoping Review and Meta-Analysis.Cardiovascular engineering and technology · 2022Pooled it
- Bioresorbable scaffolds vs. drug-eluting stents on short- and mid-term target lesion outcomes in patients after PCI: A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Influencing Factors and Prediction Model Construction of Anxiety and Depression in Patients With Coronary Heart Disease Undergoing In-Stent Restenosis.Actas espanolas de psiquiatria · 2026Article
- Auxetic Stents as a Next Generation Solution for Vascular Diseases-A Review.Cardiovascular engineering and technology · 2026Review
- An Overview of Advanced Materials and Manufacturing Strategies for 3D-Printed Bioengineered Vascular Stents: Toward Next-Generation Drug Delivery Applications.Pharmaceutics · 2026Review
- Neointimal hyperplasia and vascular restenosis: from molecular mechanisms to therapeutic interventions.Molecular biomedicine · 2026Review
- PAPP-A Protein Diagnostic and Prognostic Significance in Acute Coronary Syndromes Without Persistent ST-T-Segment Elevation.Journal of clinical medicine · 2026Article
- Underestimation of Stent Efficacy: Untreated Artery Events Distort Coronary Intervention Outcomes.Clinical cardiology · 2025Article
- A 79-Year-Old Man with a History of Ischemic Heart Disease Presenting with Right Coronary Artery Aorto-Ostial Stent Deformity and Restenosis: A Case Report.The American journal of case reports · 2025Article
- Inflammatory-Related Biomarkers in Patients Undergoing Percutaneous Transluminal Angioplasty for Femoropopliteal Artery Lesions.Acta Cardiologica Sinica · 2025Article
- Stent Underexpansion Is an Underestimated Cause of Intrastent Restenosis: Insights From RESTO Registry.Journal of the American Heart Association · 2024Observational
- Silencing ofActa biochimica et biophysica Sinica · 2024Article
- Changes of plasma Rap1A levels in patients with in-stent restenosis after percutaneous coronary intervention and the underlying mechanisms.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Genetic Variants in PHACTR1 & LPL Mediate Restenosis Risk in Coronary Artery Patients.Vascular health and risk management · 2023Article
- Restenosis of Coronary Arteries in Patients with Coronavirus Infection: Case Series.Case reports in medicine · 2023Article
- Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention.International journal of general medicine · 2023Article
- Combination of Laser Atherectomy and Super High-pressure Non-compliant Balloon to Treat Stent Under-expansion in Cases of Failed Interventional Options.Interventional cardiology (London, England) · 2023Article
- Bioresorbable vascular metallic scaffolds: Current status and research trends.Current opinion in biomedical engineering · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary stent implantation has significantly improved percutaneous coronary intervention and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. ISR after coronary angioplasty is currently one of the main limitations of this method, leading to the recurrence of exertional angina pectoris or acute coronary syndromes. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20%-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5%-10%. Evidence resulting from controlled clinical studies suggests that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. We undertook a systematic review of the pathophysiology, diagnostics and treatment options for BMS- and DES-ISR. We discuss recent randomised studies, comparing different DES or DEB used for BMS or DES-ISR treatment, as well as the use of new biovascular scafolds and the topic of scafold restenosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.